Form 4: Castle Biosciences CFO Acquires Shares from PSU Vesting

Castle Biosciences' Chief Financial Officer, Frank Stokes, acquired 8,124 shares of common stock following the vesting of performance-based stock units.

Summary

• Frank Stokes, Chief Financial Officer of Castle Biosciences Inc. (CSTL), acquired 8,124 shares of common stock.
• This acquisition resulted from the vesting of 50% of his 2024 Performance-Based Stock Units (PSUs).
• The vesting was certified by the company's board of directors on January 12, 2026, based on the satisfaction of certain performance criteria.
• The transaction date for this acquisition was January 12, 2026.
• Following this transaction, Frank Stokes beneficially owns 58,450 shares of common stock directly.
• An additional 8,124 Performance-Based Stock Units, representing the remaining 50% of the 2024 PSUs, are still outstanding and will vest upon the achievement of future milestones.

Sentiment

Score: 6

Explanation: Slightly positive. The vesting of performance-based stock units indicates that the company's board has certified the achievement of certain performance criteria, which is generally a positive sign for operational execution and management alignment.

Positives

• The vesting of 50% of the 2024 Performance-Based Stock Units (PSUs) indicates that certain performance criteria set by the board were met.
• This aligns the interests of the Chief Financial Officer with those of shareholders through equity ownership.

Future Outlook

The remaining 50% of the 2024 Performance-Based Stock Units (8,124 units) will vest subject to the achievement of certain future milestones.

Industry Context

This is a routine insider transaction filing (Form 4) common across all publicly traded companies. It reflects a standard compensation mechanism where executive performance is tied to equity vesting, a practice widely adopted to align management incentives with shareholder value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive, as the vesting indicates management achieved performance targets, aligning executive incentives with shareholder interests.

Next Steps

• Achievement of future milestones for the vesting of the remaining 50% of the 2024 Performance-Based Stock Units.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction related to the vesting of performance-based stock units for the CFO. While it indicates the achievement of past performance criteria, it does not provide new operational, financial, or strategic information that would warrant a change in investment recommendation. It's a standard disclosure of executive compensation.

Keywords

Castle Biosciences, CSTL, Form 4, insider transaction, stock units, PSUs, performance-based compensation, CFO, equity vesting, beneficial ownership